β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study
暂无分享,去创建一个
[1] P. Krawczyk,et al. Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease. , 2017, Pulmonary pharmacology & therapeutics.
[2] E. Toraih,et al. Beta2-adrenergic receptor gene haplotypes and bronchodilator response in Egyptian patients with chronic obstructive pulmonary disease. , 2017, Advances in medical sciences.
[3] J. Wedzicha,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.
[4] E. Burchard,et al. Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment. , 2016, The Journal of allergy and clinical immunology.
[5] J. Hallas,et al. Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. , 2015, Respiratory medicine.
[6] B. Nordestgaard,et al. Fibrinogen and α1-antitrypsin in COPD exacerbations , 2015, Thorax.
[7] J. Soriano,et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.
[8] Alvar Agusti,et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.
[9] J. Ribeiro,et al. Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors , 2014, Allergy, Asthma & Clinical Immunology.
[10] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[11] E. Israel,et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. , 2014, The Lancet. Respiratory medicine.
[12] J. Hallas,et al. Characteristics of undertreatment in COPD in the general population. , 2013, Chest.
[13] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[14] S. Lewitzky,et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients , 2011, The Pharmacogenomics Journal.
[15] W. Bailey,et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. , 2012, Chest.
[16] B. Nordestgaard,et al. &bgr;2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies , 2011, European Respiratory Journal.
[17] K. Helweg-larsen. The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.
[18] P. Lange,et al. Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry. , 2011, Respiratory medicine.
[19] J. Hallas,et al. The Danish National Prescription Registry , 2011, Scandinavian journal of public health.
[20] Mei-Jie Zhang,et al. Analyzing Competing Risk Data Using the R timereg Package. , 2011, Journal of statistical software.
[21] E. Silverman,et al. Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. , 2010, Respiratory medicine.
[22] B. Lipworth,et al. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. , 2009, The Journal of allergy and clinical immunology.
[23] A. Gillissen,et al. Polymorphisms of the ß2 adrenoreceptor gene in chronic obstructive pulmonary disease , 2009, Therapeutic advances in respiratory disease.
[24] B. Lipworth,et al. Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol , 2006, Thorax.
[25] Malcolm W Johnson. Molecular mechanisms of β2-adrenergic receptor function, response, and regulation , 2006 .
[26] A. Clark,et al. The role of haplotypes in candidate gene studies , 2004, Genetic epidemiology.
[27] S. Ebrahim,et al. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.
[28] Britton,et al. β2‐adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[29] S. Green,et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.
[30] B Järvholm,et al. Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. , 1993, Chest.